arrow
J

Ja Min Byun

Seoul National University Hospital
H指数:18
被引数:1,361

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)

安巴卡巴基因自体白血病细胞(PD-1和TIGIT敲低CD19 CAR-T)用于复发/难治性大B细胞淋巴瘤(CRC01-01)

Blood
IF23.1
2026-06-160
PRE
Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts

TP53突变急性髓系白血病的独特免疫表型和临床特征:高CD34/CD41表达和较低白细胞计数

2026-04-210
OAAI
Clinical Outcomes of Low-Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis

低度巨细胞病毒DNA血症在造血干细胞移植接受者中接受莱特莫韦预防的临床结局

2025-12-040
PRE
Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

在LINKER-MM1研究中,复发/难治性多发性骨髓瘤患者的linvoseltamab治疗:更长时间的随访和亚组分析

2025-11-120
OAAI
Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study

阿扎胞苷序贯R-GDP在移植不适宜的复发/难治性弥漫大B细胞淋巴瘤中的疗效:一项多中心、II期研究的初步结果

2025-07-110
OA
Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study

真实世界比较卡非佐米、来那度胺和地塞米松与伊沙佐米、来那度胺和地塞米松在复发/难治性多发性骨髓瘤患者中的应用:KMM2004研究

2025-06-040
PRE
Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/ Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study

双特异性T细胞接合器治疗复发/难治性多发性骨髓瘤的疗效和安全性: 一项基于真实世界数据的病例对照研究

2025-02-010
PRE
A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

一项评估达拉木单抗、来那度胺、硼替佐米和地塞米松在移植适用老年新诊断多发性骨髓瘤患者中有效性与安全性的II期临床研究(KMM2101)

BLOOD
IF23.1
2024-11-050
PRE
Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

卡非佐米或伊沙佐米为基础治疗方案治疗的多发性骨髓瘤患者的预后影响:反应动力学及影响因素

BLOOD
IF23.1
2024-11-050
PRE